drugset / Trial / NCT04396236
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
RandomizedParallel-groupDouble-blindTreatment
Summary
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
Timeline
- Start
- 2020-06-15
- Primary completion
- 2025-11-12
- Completion
- 2025-11-12
Outcome
Outcome not reported
Stopped (Business): “Study terminated due to strategic business decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lasmiditan | Small molecule | 25 mg | Oral |
| Subject | Lasmiditan | Small molecule | 50 mg | Oral |
| Subject | Lasmiditan | Small molecule | 100 mg | Oral |
| Subject | Lasmiditan | Small molecule | 200 mg | Oral |